Broncus Holding Corp. (2216) AI Stock Analysis

• Market Cap: HK$1.09B
• Dividend Yield: N/A
• Average Volume (3M): 5.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: -20.99%
• EPS Growth: 45.74%
• Country: HK
• Employees: 200
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Devices
• EPS (TTM): -0.24
• Shares Outstanding: 527,248,050
• 10 Day Avg. Volume: 5,683,852
• 30 Day Avg. Volume: 5,395,363
• PEG Ratio: 0.06
• Price to Book (P/B): 0.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.49
• Enterprise Value/Market Cap: 0.03
• Enterprise Value/Revenue: 0.98
• Enterprise Value/Gross Profit: 6.14
• Enterprise Value/Ebitda: -0.35
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: HK$2.50 ▲(20.77%Upside)

The overall stock score for Broncus Holding Corp. is primarily influenced by its financial performance challenges, despite positive technical momentum. The low valuation score reflects the impact of negative earnings and lack of dividends, reinforcing the need for financial improvements to enhance attractiveness.

Broncus Holding Corp. Business Overview & Revenue Model

Company Description

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.

How the Company Makes Money

Broncus Holding Corp. generates revenue through the sale of its proprietary medical devices and solutions targeted at the diagnosis and treatment of lung diseases. Key revenue streams include the direct sale of bronchoscopic devices to hospitals, clinics, and healthcare providers, as well as potential licensing agreements with other medical technology companies. The company may also generate income from service contracts and support services related to the installation and maintenance of its devices. Significant factors contributing to Broncus's earnings include its focus on innovation, strategic partnerships with research institutions, and its ability to meet the growing demand for advanced lung care solutions in the global healthcare market.

Broncus Holding Corp. Financial Statement Overview

Summary

Broncus Holding Corp. shows a mixed financial profile with strengths in gross profit margins and equity coverage but significant challenges in profitability, revenue growth, and cash flow generation. Addressing the operational inefficiencies and improving cash flow management are critical for long-term financial stability.

Income Statement

Broncus Holding Corp. displays a challenging income statement profile with consistent revenue declines from 2021 to 2024, despite experiencing a peak in 2020. The gross profit margin remains high at around 75.5% in 2024, reflecting efficient cost management relative to revenue. However, significant net losses and negative EBIT and EBITDA margins, particularly in 2024 with a net profit margin of -188.23%, indicate persistent profitability issues.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio of 96.36% in 2024, suggesting good asset coverage by equity. The debt-to-equity ratio is low at 0.0019, indicating minimal leverage. However, the company has experienced declines in total assets and stockholder equity over time, posing potential risks if trends continue.

Cash Flow

Broncus Holding Corp. faces significant cash flow challenges. The operating cash flow to net income ratio indicates a disconnect between earnings and cash flow generation, as evidenced by zero operating cash flow in 2024. The lack of free cash flow growth and historically negative free cash flow further stress the company's liquidity position.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.13M	10.26M	9.41M	10.89M	3.26M
Gross Profit	6.14M	7.23M	7.32M	8.74M	2.51M
EBITDA	-18.96M	-25.06M	-25.51M	-233.31M	-45.95M
Net Income	-15.30M	-28.09M	-28.04M	-236.18M	-48.79M
Balance Sheet
Total Assets	175.90M	195.81M	221.94M	252.81M	39.88M
Cash, Cash Equivalents and Short-Term Investments	98.82M	156.88M	187.91M	227.21M	18.79M
Total Debt	318.00K	2.35M	1.47M	1.95M	6.12M
Total Liabilities	6.42M	10.44M	8.48M	10.39M	162.32M
Stockholders Equity	169.48M	185.37M	213.46M	242.42M	-120.51M
Cash Flow
Free Cash Flow	-10.32M	-26.84M	-31.81M	-33.38M	-16.76M
Operating Cash Flow	-10.00M	-26.13M	-30.95M	-31.49M	-15.59M
Investing Cash Flow	-25.91M	5.49M	-87.57M	-1.75M	-1.09M
Financing Cash Flow	-1.02M	-1.46M	-572.00K	241.82M	32.23M

Broncus Holding Corp. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.07
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Neutral. The current price of 2.07 is below the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.13, and above the 200-day MA of 1.00, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.38 is Neutral, neither overbought nor oversold. The STOCH value of 20.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2216.

Broncus Holding Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6609	60 Neutral	HK$1.46B	―	-1.28%	―	17.45%	85.71%
2216	52 Neutral	HK$1.09B	―	-8.64%	―	-20.99%	45.74%
Sector *	51 Neutral	$7.44B	0.40	-61.90%	2.33%	17.14%	1.55%
2170	50 Neutral	HK$774.08M	―	-18.64%	―	41.62%	-22.27%
2160	47 Neutral	HK$2.12B	―	-2.19%	―	5.32%	89.43%
2235		HK$2.53B	―	-3.13%	―	―	―
2500	50 Neutral	HK$1.16B	―	-27.82%	―	-6.12%	0.43%

Broncus Holding Corp. Corporate Events

Broncus Holding Corp. Gains Approval for Innovative Lung Cancer Treatment System in China

Broncus Holding Corporation has announced that its BroncAblate® Lung Radiofrequency Ablation Generator has been approved for marketing in China by the National Medical Products Administration. This approval marks a significant step for the company as it begins the commercialization of the world’s first natural orifice transluminal radiofrequency ablation system for lung cancer. The system, which combines the BroncAblate® Generator and Catheter, offers a less invasive treatment option for lung tumors, potentially improving patient outcomes with fewer complications. This development positions Broncus Holding Corporation as a pioneer in the field of interventional lung cancer therapies, filling a global gap with its innovative approach.

Broncus Holding Corp. AGM Resolutions Passed with Strong Shareholder Support

Broncus Holding Corp. announced the successful passage of all ordinary resolutions at its annual general meeting held on May 16, 2025. This includes the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting mandates for share issuance and buyback. The approval of these resolutions reflects strong shareholder support and positions the company for continued strategic operations and governance.

Broncus Holding Corporation Announces 2025 Annual General Meeting

Broncus Holding Corporation has announced its upcoming annual general meeting scheduled for May 16, 2025, in Hangzhou, China. The meeting will address several key resolutions, including the adoption of the company’s financial statements for 2024, the re-election of directors, and the re-appointment of Ernst & Young as auditors. Additionally, the board seeks approval to issue additional shares, which could impact the company’s capital structure and market positioning.

Broncus Holding’s Innovative Lung Cancer Device Approved in China

Broncus Holding Corporation announced that its BroncAblate® Disposable Lung Radiofrequency Ablation Catheter has been approved for marketing in China by the National Medical Products Administration. This device, a world-first in natural orifice transluminal radiofrequency ablation for lung cancer, represents a significant advancement in ultra-minimally invasive interventional therapy, potentially transforming lung cancer treatment by offering a more effective and less invasive option compared to traditional methods.